Research progress on interventional therapy for treatment of pediatric tumor

doi:10.3877/cma.j.issn.2095-5782.2019.02.016

Abstract

Abstract:

In recent years, the incidence of pediatric tumors is increasing, but the research on pediatric solid tumors lags behind. Neurological tumors were the most common solid tumors in children, while other solid tumors were mainly bone tumors, kidney tumors and liver tumors. Interventional therapy for the nervous system is still not widely used. Hepatocellular carcinoma (HCC) was the most frequently treated tumor. Interventional therapy can inhibit the growth of cancer tissue, and combined surgery can significantly improve the survival of patients. More importantly, interventional therapy provides new treatment ideas for patients who cannot receive surgical treatment and more patients have more treatment options. However, there are still many problems in the application of interventional therapy in pediatric tumors, which needs our continuous efforts and innovations in clinical work.

Key words: Interventional therapy, Pediatric tumors, Transcatheter arterial, Chemoembolization, Intra-arterial chemotherapy, Hepatocellular carcinoma

Bin Wang. Research progress on interventional therapy for treatment of pediatric tumor[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 168-171.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2019.02.016

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I02/168

References 36

[1]	Smith MA, Seibel NL, AltekruseSF，et al. Outcomes for children and adolescents with cancer：challenges for the twenty-first century[J]. J Clin Oncol，2010，28(15):2625-2634.
[2]	Friedman DL, Whitton J, Leisenring W，et al. Subsequent neoplasms in 5-year survivors of childhood cancer：the Childhood Cancer Survivor Study[J]. J Natl Cancer Inst，2010，102(14):1083-1095.
[3]	Henderson T, Robison L, Mertens A，et al. Sarcomas as a subsequent malignancy in survivors of pediatric malignancy：The Childhood Cancer Survivor Study[J]. JCO，2005，23(16_suppl):8515.
[4]	deLarco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells[J]. Proc Natl AcadSci USA，1978，75(8):4001-4005.
[5]	Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004[J]. Cancer，2009，115(7):1531-1543.
[6]	Liu SJ, Zheng LY, Aweya JJ，et al. Litopenaeus vannamei hemocyanin exhibits antitumor activity in S180 mouse model in vivo[J]. PLoS One，2017，12(8):e0183783.
[7]	Blau O. Molecular investigation of Ewing sarcoma：about detecting translocations[J]. EMBO Mol Med，2012，4(6):449-450.
[8]	Northcott PA, Korshunov A, Witt H，et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol，2011，29(11):1408-1414.
[9]	Stewart LA. Chemotherapy in adult high-grade glioma：A systematic review and meta-analysis of individual patient data from 12 randomisedtrials[J]. Lancet，2002，359(9311):1011-1018.
[10]	雷彦明，旦增罗布，边巴扎西，等.西藏高原地区MDT后全麻下介入治疗儿童肝母细胞瘤一例[J].中华介入放射学电子杂志，2016，4(2):124-125.
[11]	Chen YF, Li YW, Sheih CP，et al. Renal cell carcinoma：unusual pediatric renal tumors[J]. J Formos Med Assoc，1999，98(2):118-121.
[12]	Reardon DA, Quinn JA, Vredenburgh J，et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma[J]. Cancer，2005，103(2):329-338.
[13]	Quinn JA, Jiang SX, Reardon DA，et al. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma[J]. Cancer，2009，115(13):2964-2970.
[14]	单鸿.临床介入诊疗学[M].广州：广东科技出版社，1997：47-50.
[15]	Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin：salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol，2012，35(3):555-562.
[16]	Shirota Y, Yamashita T, Terasaki S，et al. Treatment with subsegmentaltranscatheter arterial embolization for hepatocellular carcinoma：prognosis，recurrence，and effect on liver function[M]//Shirota Y，Yamashita T，Terasaki S，et al. eds. Progress in Hepatocellular Carcinoma Treatment. Tokyo：Springer Japan，2000：35-39.
[17]	Itsubo M, Koike K, Tsuno S，et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinoma[J]. Hepatogastroenterology，2002，49(45):735-739.
[18]	Hayashi K, Ina H, Tezuka M，et al. Local therapeutic results of computed tomography-guided transcatheterarterial chemoembolization for hepatocellular carcinoma：results of 265 tumors in 79 patients[J]. Cardiovasc Intervent Radiol，2007，30(6):1144-1155.
[19]	Phillips WT, BaoA, Brenner AJ，et al. Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles[J]. Adv Drug Deliv Rev，2014，76:39-59.
[20]	Liu YM, Qin H, Wang CB，et al. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer[J]. World J Gastroenterol，2006，12(31):5060-5063.
[21]	吴汉平，冯敢生.肝癌介入治疗的现状与展望[J].临床放射学杂志，2005，24(3):273-276.
[22]	祝秀丹.儿童肿瘤治疗现状[J].中国处方药，2005，3(2):24-28.
[23]	郝向东，朱铭.小儿肾胚胎瘤术前介入治疗16例[J].临床小儿外科杂志，2007，6(4):47-48.
[24]	郭芳，成守礼.小儿肾胚胎瘤的外科诊治回顾[J].山西医学院学报，1994(S1):76-77.
[25]	Li JP, Chu JP, Oh P，et al. Characterizing clinicopathological findings of transarterial chemoembolization for Wilms tumor [J]. J Urol，2010，183(3):1138-1144.
[26]	Ogita S, Tokiwa K, Taniguchi H，et al. Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants[J]. Cancer，1987，60(12):2886-2890.
[27]	Kloeckner R, Weinmann A, Prinz F，et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. BMC Cancer，2015，15:465.
[28]	Izaki K, Sugimoto K, Sugimura K，et al. Transcatheterarterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma[J]. Radiat Med，2004，22(3):155-162.
[29]	Yamamoto T, Kawarada Y, Yano T，et al. Spontaneous rupture of hemangioma of the liver：treatment with transcatheter hepatic arterial embolization[J]. Am J Gastroenterol，1991，86(11):1645-1649.
[30]	Tanaka K, Nakamura S, Numata K，et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis[J]. Cancer，1998，82(1):78-85.
[31]	贾科峰，于长路，孙诚，等.不同血供类型肝血管瘤的介入治疗效果长期随访评价[J].中华介入放射学电子杂志，2018，6(1):27-31.
[32]	刘方，张俊义，邢纪中，等.选择性动脉灌注化疗治疗小儿卵巢恶性生殖细胞瘤[J].中华小儿外科杂志，2004，25(1):87-88.
[33]	李旭彤，吴宝音，李伟男，等.介入栓塞治疗不同体积肝血管瘤的临床疗效及血流动力学特征[J].肝脏，2016，21(6):485-488.
[34]	范丽娟.膀胱肿瘤介入治疗的护理[J].中国保健营养旬刊，2013，9:5280-5281.
[35]	罗鹏飞，陈晓明，符力.肝癌介入治疗的有关问题及处理[J].中华肝脏病杂志，2002，10(3):216.
[36]	王执民.中晚期肝癌介入治疗中应该注意的几个问题[J].介入放射学杂志，2004，13(6):481-482.

Please choose a citation manager

Content to export